ArticleDigestive diseases and sciences2026
Utilization Trends of Colorectal Endoscopic Submucosal Dissection Following Reimbursement Revision and During the COVID-19 Pandemic: An Interrupted Time-Series Analysis Using a Large Japanese Claims Database.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeColorectal endoscopic submucosal dissection (ESD) is an essential oncological procedure with challenging optimal resource allocation. A 2018 reimbursement revision in Japan restricted ESD coverage to early colorectal cancer and neuroendocrine tumors. We aimed to describe utilization trends of ESD, endoscopic resection (ER), and diagnostic colonoscopy following this revision, and evaluate real-world endoscopic triage during the early stages of the COVID-19 pandemic.
methodsUsing a large Japanese claims database, we performed an interrupted time-series analysis assessing utilization changes in ESD, ER (stratified into < 2 cm and ≥ 2 cm), and colonoscopy following the 2018 revision and COVID-19 pandemic onset (April 2020).
resultsFollowing the 2018 revision, ESD showed an immediate 31% decline (incidence rate ratio [IRR] 0.69, 95% confidence interval [CI] 0.58-0.81). ER < 2 cm increased by 5% (IRR 1.05, 95%CI 1.03-1.06) and ER ≥ 2 cm increased by 13% (IRR 1.13, 95%CI 1.02-1.24), while diagnostic colonoscopy remained stable. When the COVID-19 pandemic began, ESD showed a non-significant decrease (IRR 0.89, 95%CI 0.74-1.06). Counterfactual analysis revealed suppression of ER < 2 cm (- 23.8%), ER ≥ 2 cm (- 25.0%), and diagnostic colonoscopy (- 27.4%) during April-July 2020, whereas ESD deviated minimally (- 5.8%).
conclusionThe 2018 revision was followed by decreased ESD and increased ER utilization. During the early stages of the pandemic, ER and colonoscopy fell markedly below projected trends, whereas ESD deviated minimally. These findings quantitatively document changes in procedure utilization consistent with endoscopic triage, suggesting that advanced oncological procedures were relatively prioritized and preserved during these severe system disruptions.
Indexed as
Identifiers
42149421What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.